146 related articles for article (PubMed ID: 26729900)
1. Cautious welcome for gene editing of Duchenne muscular dystrophy in animal model.
Hawkes N
BMJ; 2016 Jan; 351():h7033. PubMed ID: 26729900
[No Abstract] [Full Text] [Related]
2. Exon Snipping in Duchenne Muscular Dystrophy.
Kemaladewi DU; Cohn RD
Trends Mol Med; 2016 Mar; 22(3):187-189. PubMed ID: 26856237
[TBL] [Abstract][Full Text] [Related]
3. Genetic engineering: In vivo genome editing - growing in strength.
Koch L
Nat Rev Genet; 2016 Mar; 17(3):124. PubMed ID: 26781811
[No Abstract] [Full Text] [Related]
4. Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR/Cas9 Gene Editing Therapy.
Young CS; Mokhonova E; Quinonez M; Pyle AD; Spencer MJ
J Neuromuscul Dis; 2017; 4(2):139-145. PubMed ID: 28505980
[TBL] [Abstract][Full Text] [Related]
5. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy.
Nelson CE; Hakim CH; Ousterout DG; Thakore PI; Moreb EA; Castellanos Rivera RM; Madhavan S; Pan X; Ran FA; Yan WX; Asokan A; Zhang F; Duan D; Gersbach CA
Science; 2016 Jan; 351(6271):403-7. PubMed ID: 26721684
[TBL] [Abstract][Full Text] [Related]
6. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy.
Long C; Amoasii L; Mireault AA; McAnally JR; Li H; Sanchez-Ortiz E; Bhattacharyya S; Shelton JM; Bassel-Duby R; Olson EN
Science; 2016 Jan; 351(6271):400-3. PubMed ID: 26721683
[TBL] [Abstract][Full Text] [Related]
7. Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient.
Takeshima Y; Wada H; Yagi M; Ishikawa Y; Ishikawa Y; Minami R; Nakamura H; Matsuo M
Brain Dev; 2001 Dec; 23(8):788-90. PubMed ID: 11720794
[No Abstract] [Full Text] [Related]
8. In dogs, CRISPR fixes a muscular dystrophy.
Cohen J
Science; 2018 Aug; 361(6405):835. PubMed ID: 30166469
[No Abstract] [Full Text] [Related]
9. CRISPR technologies for the treatment of Duchenne muscular dystrophy.
Choi E; Koo T
Mol Ther; 2021 Nov; 29(11):3179-3191. PubMed ID: 33823301
[TBL] [Abstract][Full Text] [Related]
10. In Vivo Modeling of Skeletal Muscle Diseases Using the CRISPR/Cas9 System in Rats.
Nakamura K; Tanaka T; Yamanouchi K
Methods Mol Biol; 2023; 2640():277-285. PubMed ID: 36995602
[TBL] [Abstract][Full Text] [Related]
11. CRISPR Correction of Duchenne Muscular Dystrophy.
Min YL; Bassel-Duby R; Olson EN
Annu Rev Med; 2019 Jan; 70():239-255. PubMed ID: 30379597
[TBL] [Abstract][Full Text] [Related]
12. The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD.
Wang JZ; Wu P; Shi ZM; Xu YL; Liu ZJ
Brain Dev; 2017 Aug; 39(7):547-556. PubMed ID: 28390761
[TBL] [Abstract][Full Text] [Related]
13. Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA.
Long C; McAnally JR; Shelton JM; Mireault AA; Bassel-Duby R; Olson EN
Science; 2014 Sep; 345(6201):1184-1188. PubMed ID: 25123483
[TBL] [Abstract][Full Text] [Related]
14. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
[TBL] [Abstract][Full Text] [Related]
15. The Use of Antisense Oligonucleotides for the Treatment of Duchenne Muscular Dystrophy.
Relizani K; Goyenvalle A
Methods Mol Biol; 2018; 1687():171-183. PubMed ID: 29067663
[TBL] [Abstract][Full Text] [Related]
16. [Frontline studies on Duchenne muscular dystrophy treatment].
Matsuo M
No To Hattatsu; 2009 Mar; 41(2):92-5. PubMed ID: 19517771
[TBL] [Abstract][Full Text] [Related]
17. Mini-dCas13X-mediated RNA editing restores dystrophin expression in a humanized mouse model of Duchenne muscular dystrophy.
Li G; Jin M; Li Z; Xiao Q; Lin J; Yang D; Liu Y; Wang X; Xie L; Ying W; Wang H; Zuo E; Shi L; Wang N; Chen W; Xu C; Yang H
J Clin Invest; 2023 Feb; 133(3):. PubMed ID: 36512423
[TBL] [Abstract][Full Text] [Related]
18. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
[TBL] [Abstract][Full Text] [Related]
19. [Development of novel therapeutic approaches for Duchenne muscular dystrophy].
Takeshima Y
No To Hattatsu; 2014 Mar; 46(2):109-14. PubMed ID: 24738186
[No Abstract] [Full Text] [Related]
20. AAV-Mediated Somatic Gene Editing for Cardiac and Skeletal Muscle in a Large Animal Model.
Ziegler T; Bozoglu T; Kupatt C
Methods Mol Biol; 2022; 2573():63-74. PubMed ID: 36040587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
